Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company's tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/02/20 | $100,500,000 | Series B |
Atlas Venture Bay City Capital F-Prime Capital Partners Ipsen M Ventures MRL Ventures Fund RiverVest Venture Partners Solasta Ventures SV Health Investors Takeda Ventures  | undisclosed |
| 02/25/21 | $95,000,000 | Series C |
Atlas Venture Bain Capital Life Sciences Deerfield Management Company, L.P. MRL Ventures Fund RA Capital Management RiverVest Venture Partners Rock Springs Capital SV Health Investors Takeda Ventures | undisclosed |
